MRSA Study in Patients with Past Blood Infectio
- Registration Number
- CTRI/2018/08/015270
- Lead Sponsor
- BioPlx Microbiomics Inc
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1) Provision of signed and dated informed consent form.
2) Stated willingness to comply with all study procedures and availability for the duration of the study.
3) History of positive Staphylococcus aureus bacteremia as confirmed by treating physician.
4) Positive methicillin-resistant Staphylococcus aureus CHROMagar plate from screening nasal swab.
5) Agreement to adhere to the avoidance of antibiotic use unless instructed by a physician and the use of antimicrobial soaps and skin antiseptic applications throughout study duration.
1) Current use of oral, intravenous, or topical antibiotics.
2) History of autoimmune disease, immunosuppressive conditions or therapy.
3) Active diagnosis of cancer.
4) Active diagnosis of infection.
5) History of diabetes mellitus with HgbA1C > 6.5.
6) Planned pregnancy during the study or current pregnancy.
7) Febrile illness within 1 week of enrollment.
8) Receipt of a live virus vaccine within the 2 months prior to enrollment.
9) Treatment with another investigational drug or other intervention within 3 months of enrollment.
10) Chronic skin conditions such as eczema.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Presence or absence of MSSA or MRSA from axillae, nasal, throat and umbilical culture at 4 weeks.Timepoint: Weekly from weeks 1-4 after intervention.
- Secondary Outcome Measures
Name Time Method Presence or absence of MSSA or MRSA from axilla, nasal, throat, and umbilical culture at 8 weeks.Timepoint: Weekly from weeks 5-8 after intervention.